Scientists have created a vaccine that helps the body resist gaining fat. This new weekly injection works by reducing harmful ...

The mother, who resides in Campbell Hall, says his two older siblings had documented, severe reactions to the vaccine – ...

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent ...

Biotech has lagged even more. The S&P Biotechnology Select Industry Index has returned about 3 per cent annually over 10 ...

Vanguard hasn’t been immune to investors ... as it believes there is long-term potential with its vaccine development. While the strategy is overweight biotech, its limited exposure to ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

The death of President Jimmy Carter last month brought back poignant memories for people who were in the vanguard of the ...

Staphylococcus Aureus Thwarts Vaccines by Turning on a Protein That Halts Immune Response Dec. 16, 2024 — After dozens of clinical trials, there are still no effective vaccines against ...

The Vanguard Mega Cap Growth ETF has delivered a compound annual return of 13.3% since its inception in 2007, beating the average annual gain of 10.5% in the S&P 500 over the same period.